AVTX

Avalo Therapeutics, Inc.

4.38 USD
+0.06 (+1.39%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Avalo Therapeutics, Inc. stock is down -1.57% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 February’s closed higher than January.

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease and systemic juvenile idiopathic arthritis.